
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is well positioned by a diversified portfolio of Chromium, Chromium X, Visium, and Xenium platforms that address a broad range of biological analysis needs with instruments, consumables, and software. Its integrated model supports recurring consumable demand and should benefit from continued adoption of single-cell and spatial biology workflows, while its global footprint across the United States, Europe, China, and Asia-Pacific provides multiple avenues for growth. Fundamentally, the company’s value proposition rests on enabling higher-resolution biological insights at scale, which can sustain revenue momentum as customers deepen usage across research applications.
Bears say
10x Genomics is facing a fundamentally weak setup because the provided operating update showed production below expectations, with Q2 AuEq output of 96,297 oz and sales of 91,646 oz missing the 105.8 koz estimate, while gold, copper, and silver all came in under consensus. The shortfall reflects planned lower-grade and lower-recovery mining at Media Luna, and year-to-date output of 197,171 oz AuEq is tracking toward the lower half of the 420–470 koz guidance range, leaving meaningful execution risk for a second-half recovery. Even though the processing plant averaged 10,793 tpd above design and Media Luna North is expected to deliver first ore before year-end 2026, the near-term dependency on a step-up in grades and recoveries supports a negative outlook.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About 10X Genomics (TXG) Forecast
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares